Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies

Alberto Aimo, Marco Merlo, Aldostefano Porcari, Georgios Georgiopoulos, Linda Pagura, Giuseppe Vergaro, Gianfranco Sinagra, Michele Emdin, Claudio Rapezzi, Alberto Aimo, Marco Merlo, Aldostefano Porcari, Georgios Georgiopoulos, Linda Pagura, Giuseppe Vergaro, Gianfranco Sinagra, Michele Emdin, Claudio Rapezzi

Abstract

Aims: An algorithm for non-invasive diagnosis of amyloid transthyretin cardiac amyloidosis (ATTR-CA) and novel disease-modifying therapies have prompted an active search for CA. We examined the prevalence of CA in different settings based on literature data.

Methods and results: We performed a systematic search for screening studies on CA, focusing on the prevalence, sex and age distribution in different clinical settings. The prevalence of CA in different settings was as follows: bone scintigraphy for non-cardiac reasons (n = 5 studies), 1% (95% confidence interval [CI] 0%-1%); heart failure with preserved ejection fraction (n = 6), 12% (95% CI 6%-20%); heart failure with reduced or mildly reduced ejection fraction (n = 2), 10% (95% CI 6%-15%); conduction disorders warranting pacemaker implantation (n = 1), 2% (95% CI 0%-4%); surgery for carpal tunnel syndrome (n = 3), 7% (95% CI 5%-10%); hypertrophic cardiomyopathy phenotype (n = 2), 7% (95% CI 5%-9%); severe aortic stenosis (n = 7), 8% (95% CI 5%-13%); autopsy series of 'unselected' elderly individuals (n = 4), 21% (95% CI 7%-39%). The average age of CA patients in the different settings ranged from 74 to 90 years, and the percentage of men from 50% to 100%. Many patients had ATTR-CA, but the average percentage of patients with amyloid light-chain (AL) CA was up to 18%.

Conclusions: Searching for CA in specific settings allows to identify a relatively high number of cases who may be eligible for treatment if the diagnosis is unequivocal. ATTR-CA accounts for many cases of CA across the different settings, but AL-CA is not infrequent. Median age at diagnosis falls in the eighth or ninth decades, and many patients diagnosed with CA are women.

Keywords: Autopsy; Cardiac amyloidosis; Carpal tunnel syndrome; Diagnosis; Epidemiology; Heart failure; Hypertrophy; Red flags; Scintigraphy; Screening.

© 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Figures

Figure 1
Figure 1
Prevalence of cardiac amyloidosis (CA) in different settings. Except for two specific settings (bone scintigraphy for non‐cardiac reasons and autopsy in unselected elderly individuals), the mean and 95% confidence interval (CI) or the range of prevalence of CA across studies (blue), the percentage of males out of all patients with CA (average and range; red), the mean/median age of patients with CA (brown), and the percentage of patients with amyloid light‐chain (AL) CA out of all patients with CA (green) are reported. Information on the original studies is reported in Table 1. HCM, hypertrophic cardiomyopathy; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; M, men; W, women.
Figure 2
Figure 2
Prevalence of incidental myocardial uptake of bone tracers among men (M) and women (W) from the general population. See Table 1 for details on the original studies. CA, cardiac amyloidosis.
Figure 3
Figure 3
Prevalence of cardiac amyloidosis (CA) in patients with severe aortic stenosis referred to surgical or transcatheter aortic valve replacement. Prevalence values were calculated as the number of cases of CA among men (M) and women (W) divided by the number of M and W, respectively. In the study by Singal et al., no patient had CA diagnosed based on histology. Nitsche et al. considered the number of M and W with a Perugini score 2–3 instead of the number of M and W with CA (not provided). See Table 1 for further details on the original studies.

References

    1. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real‐world study using US claims data. Blood Adv. 2018;2:1046–53.
    1. Gilstrap LG, Dominici F, Wang Y, el‐Sady MS, Singh A, di Carli MF, et al. Epidemiology of cardiac amyloidosis‐associated heart failure hospitalizations among fee‐for‐service Medicare beneficiaries in the United States. Circ Heart Fail. 2019;12:e005407.
    1. Pozsonyi Z, Peskó G, Takács H, Csuka D, Nagy V, Szilágyi Á, et al. Variant transthyretin amyloidosis (ATTRv) in Hungary: first data on epidemiology and clinical features. Genes. 2021;12:1152.
    1. Coelho T, Maurer MS, Suhr OB. THAOS – the Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild‐type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76.
    1. Moliner AM, Waligora J. The European Union policy in the field of rare diseases. Adv Exp Med Biol. 2017;1031:561–87.
    1. Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint position statement on the evaluation and management of patients with cardiac amyloidosis. Can J Cardiol. 2020;36:322–34.
    1. Garcia‐Pavia P, Bengel F, Brito D, Damy T, Duca F, Dorbala S, et al. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021;23:895–905.
    1. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al.; Japanese Circulation Society Joint Working Group . JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020;84:1610–71.
    1. Kittleson MM, Maurer MS, Ambardekar AV, Bullock‐Palmer RP, Chang PP, Eisen HJ, et al.; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology . Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142:e7–22.
    1. Vergaro G, Aimo A, Barison A, Genovesi D, Buda G, Passino C, et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. 2020;27:1806–15.
    1. Newcombe RG. Two‐sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–72.
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ. 2003;327:557–60.
    1. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65:934–9.
    1. Cuscaden C, Ramsay SC, Prasad S, Goodwin B, Smith J. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020;28:2845–56.
    1. Bianco M, Parente A, Biolè C, Righetti C, Spirito A, Luciano A, et al. The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy. J Nucl Cardiol. 2021;28:825–30.
    1. Mohamed‐Salem L, Santos‐Mateo JJ, Sanchez‐Serna J, Hernández‐Vicente Á, Reyes‐Marle R, Castellón Sánchez MI, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018;270:192–6.
    1. Kim HM, Sohn DW, Paeng JC. Prevalence of positive 99mTc‐DPD scintigraphy as an indicator of the prevalence of wild‐type transthyretin amyloidosis in the elderly. Int Heart J. 2019;60:643–7.
    1. Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR‐related subclinical amyloidosis with 99mTc‐DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2.
    1. Lindmark K, Pilebro B, Sundström T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021;8:745–9.
    1. González‐López E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐del Moral FJ, Cobo‐Marcos M, Robles C, et al. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94.
    1. Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, et al. Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail. 2020;8:712–24.
    1. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2021;6:1267–74.
    1. Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Méjean S, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016;32:1403–13.
    1. Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid. 2017;24:253–5.
    1. Devesa A, Camblor Blasco A, Pello Lázaro AM, Askari E, Lapeña G, Gómez Talavera S, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail. 2021;8:2856–65.
    1. López‐Sainz Á, de Haro‐Del Moral FJ, Dominguez F, Restrepo‐Cordoba A, Amor‐Salamanca A, Hernandez‐Hernandez A, et al. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders. Amyloid. 2019;26:156–63.
    1. Goland S, Volodarsky I, Fabricant Y, Livschitz S, Tshori S, Cuciuc V, et al. Wild‐type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. PLoS One. 2021;16:e0254104.
    1. Vianello PF, La Malfa G, Tini G, Mazzola V, Miceli A, Santolini E, et al. Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study. Int J Cardiol. 2021;329:144–7.
    1. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72:2040–50.
    1. Zegri‐Reiriz I, de Haro‐Del Moral FJ, Dominguez F, Salas C, de la Cuadra P, Plaza A, et al. Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome. J Cardiovasc Transl Res. 2019;12:507–13.
    1. Sperry BW, Khedraki R, Gabrovsek A, Donnelly JP, Kilpatrick S, Shapiro D, et al. Cardiac amyloidosis screening at trigger finger release surgery. Am J Cardiol. 2021;160:96–8.
    1. Damy T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37:1826–34.
    1. Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020;300:191–5.
    1. Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Res 2017;19:98.
    1. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9:e005066.
    1. Singal AK, Bansal R, Singh A, Dorbala S, Sharma G, Gupta K, et al. Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study. JACC CardioOncology. 2021;3:565–76.
    1. Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, et al. Light‐chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020;22:1852–62.
    1. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77:128–39.
    1. Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87.
    1. Scully PR, Treibel TA, Fontana M, Lloyd G, Mullen M, Pugliese F, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71:463–4.
    1. Lie JT, Hammond PI. Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old. Mayo Clin Proc. 1988;63:552–64.
    1. Roberts WC, Shirani J. Comparison of cardiac findings at necropsy in octogenarians, nonagenarians, and centenarians. Am J Cardiol. 1998;82:627–31.
    1. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: a population‐based autopsy study. Ann Med. 2008;40:232–9.
    1. Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post‐mortem examination. Front Cardiovasc Med. 2021;8:749523.
    1. Fosbøl EL, Rørth R, Leicht BP, Schou M, Maurer MS, Kristensen SL, et al. Association of carpal tunnel syndrome with amyloidosis, heart failure, and adverse cardiovascular outcomes. J Am Coll Cardiol. 2019;74:15–23.
    1. Garcia‐Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554–68.
    1. Yilmaz A, Bauersachs J, Bengel F, Büchel R, Kindermann I, Klingel K, et al. Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol. 2021;110:479–506.
    1. Falk RH, Alexander KM, Liao R, Dorbala S. AL (light‐chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323–41.
    1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2 – diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27:659–73.
    1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2 – evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–123.
    1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.
    1. Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‐3,3‐diphosphono‐1,2‐propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076–84.
    1. Caponetti AG, Rapezzi C, Gagliardi C, Milandri A, Dispenzieri A, Kristen AV, et al. Sex‐related risk of cardiac involvement in hereditary transthyretin amyloidosis: insights from THAOS. JACC Heart Fail. 2021;9:736–46.
    1. Sotomi Y, Hikoso S, Nakatani D, Mizuno H, Okada K, Dohi T, et al.; PURSUIT‐HFpEF Investigators . Sex differences in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10:e018574.
    1. Mitake T, Iwatsuki K, Hirata H. Differences in characteristics of carpal tunnel syndrome between male and female patients. J Orthop Sci. 2020;25:843–6.
    1. Rapezzi C, Giannini F, Campo G. Aortic stenosis, transcatheter aortic valve replacement and transthyretin cardiac amyloidosis: are we progressively unraveling the tangle? Eur J Heart Fail. 2021;23:259–63.
    1. Kristen AV, Schnabel PA, Winter B, Helmke BM, Longerich T, Hardt S, et al. High prevalence of amyloid in 150 surgically removed heart valves – a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol. 2010;19:228–35.
    1. Mangione PP, Verona G, Corazza A, Marcoux J, Canetti D, Giorgetti S, et al. Plasminogen activation triggers transthyretin amyloidogenesis in vitro. J Biol Chem. 2018;293:14192–9.
    1. Merlo M, Porcari A, Pagura L, Cameli M, Vergaro G, Musumeci B, et al. A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization – the first insight from the AC‐TIVE study. Eur J Prev Cardiol. 2022;29:e173–7.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren